GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » EV-to-FCF

DARE (Dare Bioscience) EV-to-FCF : -2.23 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dare Bioscience's Enterprise Value is $17.93 Mil. Dare Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-8.02 Mil. Therefore, Dare Bioscience's EV-to-FCF for today is -2.23.

The historical rank and industry rank for Dare Bioscience's EV-to-FCF or its related term are showing as below:

DARE' s EV-to-FCF Range Over the Past 10 Years
Min: -8.35   Med: 1.43   Max: 1.72
Current: -2.23

During the past 12 years, the highest EV-to-FCF of Dare Bioscience was 1.72. The lowest was -8.35. And the median was 1.43.

DARE's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs DARE: -2.23

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Dare Bioscience's stock price is $3.18. Dare Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.621. Therefore, Dare Bioscience's PE Ratio (TTM) for today is At Loss.


Dare Bioscience EV-to-FCF Historical Data

The historical data trend for Dare Bioscience's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience EV-to-FCF Chart

Dare Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.91 -2.05 -4.05 -2.00 -0.55

Dare Bioscience Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.55 -1.60 -1.89 -2.23

Competitive Comparison of Dare Bioscience's EV-to-FCF

For the Biotechnology subindustry, Dare Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dare Bioscience's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dare Bioscience's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Dare Bioscience's EV-to-FCF falls into.



Dare Bioscience EV-to-FCF Calculation

Dare Bioscience's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=17.925/-8.021
=-2.23

Dare Bioscience's current Enterprise Value is $17.93 Mil.
Dare Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dare Bioscience  (NAS:DARE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Dare Bioscience's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.18/-0.621
=At Loss

Dare Bioscience's share price for today is $3.18.
Dare Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.621.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Dare Bioscience EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Dare Bioscience Business Description

Traded in Other Exchanges
N/A
Address
3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Executives
Sophia Nnenna Ononye-onyia director 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson director, officer: Chef Executive Officer 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair officer: Chief Strategy Officer C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley director 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz director 1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman director C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert officer: Chief Financial Officer C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof officer: SVP, Chief Scientific Officer C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz officer: SVP, Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle director VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal officer: VP, General Counsel C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill officer: Principal Accounting Officer 15 GREENBRIAR CIRCLE, ANDOVER MA 01810